Literature DB >> 9140304

Pilot studies for proficiency testing using fluorescence in situ hybridization with chromosome-specific DNA probes: a College of American Pathologists/American College of Medical Genetics Program.

G W Dewald1, A R Brothman, M G Butler, L D Cooley, S R Patil, I A Saikevych, N R Schneider.   

Abstract

Fluorescence in situ hybridization using chromosome-specific DNA probes is rapidly becoming part of clinical laboratory practice for certain congenital and neoplastic disorders. Current legislation requires proficiency testing for clinical laboratory studies. To evaluate the efficacy of fluorescence in situ hybridization proficiency testing, we invited 19 representative institutions to participate in three pilot studies. One study used probes for the X and Y chromosomes to evaluate metaphase spreads and interphase nuclei. Another study used probes for bcr and abl to detect bcr/abl fusion in interphase nuclei in chronic myelogenous leukemia. The third study used a D22S75 probe to detect microdeletions in metaphase spreads from a patient with velocardiofacial syndrome. The results of these studies demonstrate that proficiency testing with fluorescence in situ hybridization is attainable using either metaphase or interphase preparations, and that either microscope slides or fixed cell pellets are suitable.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9140304      PMCID: PMC6028008     

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  12 in total

1.  Medicare, Medicaid and CLIA programs; regulations implementing the Clinical Laboratory Improvement Amendments of 1988 (CLIA)--HCFA. Final rule with comment period.

Authors: 
Journal:  Fed Regist       Date:  1992-02-28

2.  Fluorescence in situ hybridization: a sensitive method for trisomy 8 detection in bone marrow specimens.

Authors:  R B Jenkins; M M Le Beau; W J Kraker; T J Borell; P G Stalboerger; E M Davis; L Penland; A Fernald; R Espinosa; D J Schaid
Journal:  Blood       Date:  1992-06-15       Impact factor: 22.113

3.  Dynamics of chromosome spreading.

Authors:  J L Spurbeck; A R Zinsmeister; K J Meyer; S M Jalal
Journal:  Am J Med Genet       Date:  1996-02-02

4.  Toward quality assurance for metaphase FISH: a multi-center experience.

Authors:  G Dewald; R Stallard; P I Bader; K Chen; J Zenger-Hain; C J Harris; R Higgins; B Hirsch; W T Hsu; E Johnson; V Kubic; T W Kurczynski; J M Malone; D J McCorquodale; K Meilinger; L F Meisner; J W Moore; S Schwartz; S Siembieda; P D Storto; G Vance; P Van Tuinen; A Wiktor; J F Yung
Journal:  Am J Med Genet       Date:  1996-09-06

5.  Efficacy of fluorescence in situ hybridization for detecting PML/RARA gene fusion in treated and untreated acute promyelocytic leukemia.

Authors:  C R Schad; C A Hanson; E Paietta; J Casper; S M Jalal; G W Dewald
Journal:  Mayo Clin Proc       Date:  1994-11       Impact factor: 7.616

6.  Fluorescence in situ hybridization with X and Y chromosome probes for cytogenetic studies on bone marrow cells after opposite sex transplantation.

Authors:  G W Dewald; C R Schad; E R Christensen; M E Law; A R Zinsmeister; P G Stalboerger; S M Jalal; R C Ash; R B Jenkins
Journal:  Bone Marrow Transplant       Date:  1993-08       Impact factor: 5.483

7.  The application of fluorescent in situ hybridization to detect Mbcr/abl fusion in variant Ph chromosomes in CML and ALL.

Authors:  G W Dewald; C R Schad; E R Christensen; A L Tiede; A R Zinsmeister; J L Spurbeck; S N Thibodeau; S M Jalal
Journal:  Cancer Genet Cytogenet       Date:  1993-11

8.  DiGeorge syndrome: part of CATCH 22.

Authors:  D I Wilson; J Burn; P Scambler; J Goodship
Journal:  J Med Genet       Date:  1993-10       Impact factor: 6.318

9.  Use of fluorescence in situ hybridization (FISH) in the diagnosis of DiGeorge sequence and related diseases.

Authors:  R S Larson; M G Butler
Journal:  Diagn Mol Pathol       Date:  1995-12

10.  DNA fluorescent probes for diagnosis of velocardiofacial and related syndromes.

Authors:  P A Crifasi; V V Michels; D J Driscoll; S M Jalal; G W Dewald
Journal:  Mayo Clin Proc       Date:  1995-12       Impact factor: 7.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.